Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has hailed its first product, the i/Blue(TM) Imaging System, as a breakthrough technology that will advance the accuracy and efficiency of bladder cancer detection and removal, thus helping it capture some market share. The global endoscopy market is valued at $46 billion, of which Imagin is positioned to target $400 million with its bladder cancer detection product. An article detailing this reads, “The company’s patented ultrasensitive imaging product based on optics and light sensors, has potential early-stage cancer-detection abilities. The company’s first target for treatment is bladder cancer.” According to the article, this product provides several advantages, such as improved visualization during minimally invasive surgery (“MIS”). With the i/Blue Imaging System, “the surgeon can simultaneously view both white and blue light video streams in a single frame and in real-time on the surgical monitor, without having to toggle between the two images.”
To view the full article, visit https://ibn.fm/gp3xm
About Imagin Medical
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.